🟢 Beam Therapeutics is trading 4.11% up today following FDA clearance for BEAM-304 and positive clinical data

Beam Therapeutics is trading at $37.29 (+4.11%) following recent FDA clearance for BEAM-304 and positive clinical data for BEAM-302.

• The company recently received FDA clearance for BEAM-304 and reported encouraging clinical data for BEAM-302, leading H.C. Wainwright to reiterate a Buy rating with an $80 price target.
• Shares touched a new 52-week high near $36.89, suggesting strong momentum is carrying into the open as the stock benefits from broader biotech sector strength.